Evidence map›Paper›PMID 39339280›Full record

ArticleMolecules (Basel, Switzerland)2024

Novel Autotaxin Inhibitor ATX-1d Significantly Enhances Potency of Paclitaxel-An In Silico and In Vitro Study.

Prateek Rai, Christopher J Clark, Carl B Womack, Curtis Dearing, Joshua Thammathong, Derek D Norman, Gábor J Tigyi, Subhabrata Sen, Kevin Bicker, April M Weissmiller and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Prateek RaiMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.ORCID 0000-0002-3887-2694
Christopher J ClarkMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
Carl B WomackDepartment of Biology, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
Curtis DearingDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, TN 37132, USA.ORCID 0009-0008-3449-4914
Joshua ThammathongDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
Derek D NormanDepartment of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
Gábor J TigyiDepartment of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA.ORCID 0000-0001-5371-171X
Subhabrata SenDepartment of Chemistry, School of Natural Sciences, Shiv Nadar Institution of Eminence Deemed to be University, Dadri 201314, UP, India.
Kevin BickerMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
April M WeissmillerMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.ORCID 0000-0003-4505-0530
Souvik BanerjeeMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.ORCID 0000-0002-7811-2577

Funding

Middle Tennessee State University 210268Wellcome Trust 220000
6 · The paper itself

Abstract

The development of drug resistance in cancer cells poses a significant challenge for treatment, with nearly 90% of cancer-related deaths attributed to it. Over 50% of ovarian cancer patients and 30-40% of breast cancer patients exhibit resistance to therapies such as Taxol. Previous literature has shown that cytotoxic cancer therapies and ionizing radiation damage tumors, prompting cancer cells to exploit the autotaxin (ATX)-lysophosphatidic acid (LPA)-lysophosphatidic acid receptor (LPAR) signaling axis to enhance survival pathways, thus reducing treatment efficacy. Therefore, targeting this signaling axis has become a crucial strategy to overcome some forms of cancer resistance. Addressing this challenge, we identified and assessed ATX-1d, a novel compound targeting ATX, through computational methods and in vitro assays. ATX-1d exhibited an IC

Indexed as

PaclitaxelPhosphoric Diester HydrolasesAnimalsCell Line, TumorCell SurvivalComputer SimulationDrug SynergismHumansLysophospholipase DMiceMolecular Docking SimulationLysophospholipase DPaclitaxelPhosphoric Diester Hydrolasesautotaxinbreast cancercombination therapymelanomamolecular simulationsQM/MM-GBSASAPT

Identifiers

PMID39339280
PMCPMC11434342

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.